Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of Alzheimer’s disease

Expert Opinion on Emerging Drugs

Volumn 22, Issue 1, 2017, Pages 101-105

  Calhoun, Amanda ^a   Ko, Je ^a   Grossberg, George T ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 HT6 receptor; Alzheimer s disease; idalopirdine

Indexed keywords

DONEPEZIL; IDALOPIRDINE; INTEPIRDINE; MEMANTINE; PF 05212377; SEROTONIN; SEROTONIN 6 ANTAGONIST; SUVN 502; UNCLASSIFIED DRUG; (2-(6-FLUORO-1H-INDOL-3-YL)-ETHYL)-(3-(2,2,3,3-TETRAFLUOROPROPOXY)BENZYL)AMINE; 3-BENZENESULFONYL-8-PIPERAZIN-1-YLQUINOLINE; BENZYLAMINE DERIVATIVE; INDOLE DERIVATIVE; QUINOLINE DERIVATIVE; SEROTONIN 6 RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SULFONE;

ALZHEIMER DISEASE; COGNITION; DRUG EFFICACY; DRUG TARGETING; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SYMPTOMATOLOGY; AGED; ANIMAL; DRUG DESIGN; DRUG EFFECTS; METABOLISM;

AGED; ALZHEIMER DISEASE; ANIMALS; BENZYLAMINES; DRUG DESIGN; HUMANS; INDOLES; QUINOLINES; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; SULFONES;

EID: 85014639884     PISSN: 14728214     EISSN: 17447623     Source Type: Journal    
DOI: 10.1080/14728214.2017.1293651     Document Type: Review

References (45)

1. Hebert L, Weauve J, Scherr PA, et al. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. 2013;80:1778–1783.
2. Alzheimer’s Association. 2016 Alzheimer’s disease facts and figures. Alzheimers Dement. 2016;12:459–509.
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Fifth ed. Arlington:American Psychiatric Publishing; 2013.
4. Zhao QF, Tan L, Wang HF, et al. The prevalence of neuropsychiatric symptoms in alzheimer’s disease:systematic review and meta-analysis. J Affect Disord. 2016;15:264–271.
5. Sallim AB, Sayampanathan AA, Cuttilan A, et al. Prevalence of mental health disorders among caregivers of patients with alzheimer’s disease. J Am Med Dir Assoc. 2015;16:1034–1041.
6. Johnson JW, Kotermanski SE., Mechanism of action of memantine. Curr Opin Pharmacol. 2006;6:61–67.
7. Upton N, Chuang TT, Hunter AJ, et al. 5-HT6 receptor antagonists as novel cognitive enhancing agents for alzheimer’s disease. Neurotherapeutics. 2008;5:458–469.• This article discusses the effect of 5-HT6 receptor antagonists on the serotonergic, GABAergic, noradrenergic, and dopaminergic neurotransmitter pathways.
8. Tan CC, Yu JT, Wang HF, et al. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of alzheimer’s disease:a systematic review and meta-analysis. J Alzheimers Dis. 2014;41:615–631.
9. Birks J, Harvey RJ. Donepezil for dementia due to alzheimer’s disease. Cochrane Database Syst Rev. 2006;Issue 1. Art. No.CD001190.
10. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia:evidence review for a clinical practice guideline. Ann Intern Med. 2008;148:379–397.
11. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with alzheimer’s disease (AD2000):randomised double-blind trial. Lancet. 2004;363:2105–2115.
12. Birks JS. Cholinesterase inhibitors for alzheimer’s disease. Cochrane Database Syst Rev. 2006;Issue 1. Art. No.CD005593.
13. Gauthier S, Molinuevo JL. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe alzheimer’s disease. Alzheimers Dement. 2013;9:326–331.
14. Herrik KF, Mørk A, Richard N, et al. The 5-HT6 receptor antagonist idalopirdine potentiates the effects of acetylcholinesterase inhibition on neuronal network oscillations and extracellular acetylcholine levels in the rat dorsal hippocampus. Neuropharmacology. 2016;107:351–363.•• This article outlines the rat studies that have demonstrated the effectiveness of 5-HT6 antagonists as additive therapy to donepezil. Idalopirdine was shown to enhance the effects of donepezil on acetylcholine levels.
15. Amat-Foraster M, Leiser SC, Herrik KF, et al. The 5-HT6 receptor antagonist idalopirdine potentiates the effects of donepezil on gamma oscillations in the frontal cortex of anesthetized and awake rats without affecting sleep-wake architecture. Neuropharmacology. 2016;113(Pt A):45–59.•• This article outlines the rat studies that have demonstrated the effectiveness of 5-HT6 antagonists as additive therapy to donepezil. Idalopirdine was shown to enhance the procognitive effects of donepezil, specifically on gamma oscillations.
16. Serrano-Pozo A, Frosch MP, Masliah E, et al. Neuropathological alterations in Alzheimer’s disease. Cold Spring Harb Perspect Med. 2011;1(1):a006189.
17. Nelson PT, Braak H, Markesbery WR. Neuropathology and cognitive impairment in alzheimer’s disease:a complex but coherent relationship. J Neuropathol Exp Neurol. 2009;68:1–14.
18. Braak H, Braak E. Neuropathological stageing of alzheimer-related changes. Acta Neuropathol. 1991;82:239–259.
19. Terry AV, Jr, Buccafusco JJ. The cholinergic hypothesis of age and alzheimer’s disease-related cognitive deficits:recent challenges and their implications for novel drug development. J Pharmacol Exp Ther. 2003;306:821–827.
20. Gérard C, El Mestikawy S, Lebrand C, et al. Quantitative RT-PCR distribution of serotonin 5-HT6 receptor mRNA in the central nervous system of control or 5,7-dihydroxytryptamine-treated rats. Synapse. 1996;23:164–173.
21. Ward RP, Hamblin MW, Lachowicz JE, et al. Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry. Neuroscience. 1995;64:1105–1111.
22. Monsma FJ, Jr, Shen Y, Ward RP, et al. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol. 1993;43:320–327.
23. Murphy C, Nordin S, Jinich S. Very early decline in recognition memory for odors in Alzheimer’s disease. Aging Neuropsychol Cogn. 1999;6:229–240.
24. Yager LM, Garcia AF, Wunsch AM, et al. The ins and outs of the striatum:role in drug addiction. Neuroscience. 2015;301:529–541.
25. Woolley ML, Bentley JC, Sleight AJ, et al. A role for 5-HT6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology. 2001;41:210–219.
26. Bentley JC, Bourson A, Boess FG, et al. Investigation of stretching behaviour induced by selective 5-HT6 receptor antagonist, Ro 04-6790, in rats. Br J Pharmacol. 1999;126:1537–1542.
27. Francis PT, Palmer AM, Snape M, et al. The cholinergic hypothesis of alzheimer’s disease:a review of progress. J Neurol Neurosurg Psychiatry. 1999;66:137–147.
28. Perry E, Walker M, Grace J, et al. Acetylcholine in mind:a neurotransmitter correlate of consciousness? Trends Neurosci. 1999;22:273–280.
29. Marcos B, Chuang TT, Gil-Bea FJ, et al. Effects of 5-HT6 receptor antagonist and cholinesterase inhibition on models of cognitive impairment in the rat. Br J Pharmacol. 2008;155:434–440.
30. Woods S, Clarke NN, Layfield R, et al. 5-HT6 receptor agonists and antagonists enhance learning and memory in a conditioned emotion response paradigm by modulation of cholinergic and glutaminergic mechanisms. Br J Pharmacol. 2012;167:436–449.
31. Dawson LA, Nguyen HQ, Li P. In vivo effects of the 5-HT(6) antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate. Br J Pharmacol. 2000;130:23–26.
32. Dawson LA, Nguyen HQ, Li P. The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology. 2001;25:662–668.
33. Francis PT, Sims NR, Procter AW, et al. Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in alzheimer’s disease:investigative and therapeutic perspectives. J Neurochem. 1993;60:1589–1604.
34. Palmer AM. Neurochemical studies of Alzheimer’s disease. Neurodegeneration. 1996;5:381–391.
35. Woolley ML, Marsden CA, Fone KC. 5-HT6 receptors. Curr Drug Targets CNS Neurol Disord. 2004;3:59–79.
36. Schechter LE, Lin Q, Smith DL, et al. Neuropharmacological profile of novel and selective 5-HT6 receptor agonists:WAY-181187 and WAY-208466. Neuropsychopharmacology. 2008;33:1323–1335.
37. Gérard C, Martres MP, Lefèvre K, et al. Immuno-localization of serotonin 5-HT6 receptor-like material in the rat central nervous system. Brain Res. 1997;746:207–219.
38. Stephenson D, Perry D, Bens C, et al. Charting a path toward combination therapy for alzheimer’s disease. Expert Rev Neurother. 2015;15:107–113.
39. Lundbeck H, A/S. Randomised, double-blind, parallel-group, placebo-controlled study of Lu AE58054 in patients with mild to moderate Alzheimer’s disease treated with an acetylcholinesterate inhibitor. Available at:https://clinicaltrials.gov/ct2/show/NCT02006654. NLM identifier:NCT02006654. [Last accessed 1December 2016]
40. Lundbeck H, A/S. Randomised, double-blind, parallel-group, placebo-controlled, fixed-dose study of Lu AE58054 in patients with mild-moderate Alzheimer’s disease treated with donepezil. Available at:https://clinicaltrials.gov/ct2/show/NCT01955161. NLM identifier:NCT01955161. [Last accessed 1 December 2016]
41. Lundbeck provides update on Phase 3 Study for Alzheimer’s treatment. Drug Discov Dev. 2016; Available at http://www.dddmag.com/news/2016/09/lundbeck-provides-update-phase-3-study-alzheimers-treatment [Last accessed 1December 2016].
42. Axovant sciences Ltd. A phase 3, double-blind, randomized study of RVT-101 versus plaecbo when added to existing stable donepezil treatment in subjects with mild to moderate Alzheimer’s disease. Available at. https://clinicaltrials.gov/ct2/show/NCT02585934. NLM identifier:02585934. [Last accessed 1 December 2016]
43. Suven Inc, Suven Life Sciences. A phase 2a multicenter, randomized, double-Blind, parallel group, 26-week, placebo-controlled study of SUVN-502 in subjects with moderate Alzheimer’s disease currently treated with onepezil hydrochloride and memantine hydrochloride. ClinicalTrials.gov. [Internet]. Cited November 2016. Available at:https://clinicaltrials.gov/ct2/show/NCT02580305 NLM identifier:NCT02580305.
44. Hayes E. Pfizer’s failed 5-HT6 Alzheimer’s drug leaves hope for class. Scrip intelligence, 2016. Available at:https://scrip.pharmamedtechbi.com/-/media/Supporting-Documents/Scrip-Issue-PDFs/2016/scrip_3814.pdf?la=en. [Last accessed 1 December 2016]
45. Dudek M, Marcinkowska M, Bucki A, et al. Idalopirdine-a small molecule antagonist of 5-HT6 with therapeutic potential against obesity. Metab Brain Dis. 2015;30:1487–1494.